Literature DB >> 1689659

Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation.

H G Drexler1, S M Gignac, G R Pettit, A V Hoffbrand.   

Abstract

In this study we have examined the immunostimulatory effects of the macrocyclic lactone bryostatin 1 on various aspects of B cell activation and proliferation using human tonsillar B cells. Bryostatin 1 is an activator of protein kinase C (PKC) and its properties were compared to those of the classical PKC activator phorbol 12-myristate 13-acetate (PMA), a phorbol ester. Time-course kinetics and dose-response curves of RNA and DNA synthesis induced by bryostatin 1 or PMA were comparable, albeit the phorbol ester was significantly more potent. The responses triggered by both bryostatin 1 and PMA could be blocked by the PKC inhibitor H7. Bryostatin 1 and PMA mediated similar effects with regard to the activation parameters, increase in cell size, expression of activation-associated antigens and hyperexpression of major histocompatibility complex class II antigens. Addition of the calcium ionophore A23187 to bryostatin 1-treated cultures resulted in synergistically enhanced activation and proliferation responses, and this potentiation by A23187 could be inhibited by cyclosporin A. Bryostatin 1 antagonized the effects of PMA-triggered stimulation in a time- and dose-dependent manner. The basis for this modulation of PMA-induced effects and the reason for the difference in the abilities of the two agents to stimulate B cells is unclear; possibly, bryostatin 1 and PMA activate different isoforms of PKC and elicit different signals on intracellular biochemical pathways. Bryostatin 1 lacks the tumor-promoting activity of PMA and is a potent anti-neoplastic substance. These features together with its immunomodulatory properties qualify bryostatin 1 as a candidate for in vivo use as a biological response modifier.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689659     DOI: 10.1002/eji.1830200118

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Early response gene signalling in bryostatin-stimulated primary B chronic lymphocytic leukaemia cells in vitro.

Authors:  Z Q Ning; T Hirose; R Deed; J Newton; J J Murphy; J D Norton
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

2.  Depressed T-cell proliferation associated with susceptibility to experimental Taenia crassiceps infection.

Authors:  E Sciutto; G Fragoso; M Baca; V De la Cruz; L Lemus; E Lamoyi
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

3.  A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

Authors:  J Prendiville; D Crowther; N Thatcher; P J Woll; B W Fox; A McGown; N Testa; P Stern; R McDermott; M Potter
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

4.  A phase II study of bryostatin 1 in metastatic malignant melanoma.

Authors:  D J Propper; V Macaulay; K J O'Byrne; J P Braybrooke; S M Wilner; T S Ganesan; D C Talbot; A L Harris
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

5.  The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.

Authors:  Victoria E Walker-Sperling; Christopher W Pohlmeyer; Patrick M Tarwater; Joel N Blankson
Journal:  EBioMedicine       Date:  2016-04-18       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.